REG-Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses
Oculis received positive pre-IND feedback from the FDA for Privosegtor, supporting a regulatory pathway for the treatment of acute multiple sclerosis relapses. The agency confirmed that existing data can be cross-referenced for a new IND submission, which is now planned for the fourth quarter of 2026 without the need for additional preclinical studies.
Key figures
- Drug Name
- Privosegtor
- Phase Of Trial
- Phase 2
- Dose
- 3mg/kg
- Primary endpoint
- 3 months
- Planned ind submission
- fourth quarter of 2026
- Orphan drug designation
- Yes
- Breakthrough therapy designation
- Yes
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.